Gastroesophageal Junction Carcinoma
11
6
6
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
45.5%
5 terminated out of 11 trials
0.0%
-86.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (11)
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
A Study of SGN-ALPV in Advanced Solid Tumors
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
A Study of SGN-STNV in Advanced Solid Tumors
A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma